

21 July 2015

## **ANP Licensing Partner Cortendo Announces Plans to Conduct Registered Initial Public Offering**

Antisense Therapeutics Ltd (ANP) wishes to advise of news from its ATL1103 licensing partner Cortendo in regard to their plans to conduct a registered initial public offering of common shares in the United States.

Please see attached press release from Cortendo.

### **Contact Information:**

Website: [www.antisense.com.au](http://www.antisense.com.au)

Managing Director: Mark Diamond +61 (0)3 9827 8999

### **About Antisense Therapeutics Limited**

Antisense Therapeutics Limited is an Australian publicly listed biopharmaceutical drug discovery and development company. Its mission is to create, develop and commercialise second generation antisense pharmaceuticals for large unmet markets. Antisense Therapeutics has 4 products in its development pipeline that it has in-licensed from Isis Pharmaceuticals Inc. (ISIS), a world leader in antisense drug development and commercialisation - ATL1102 (injection) which has successfully completed a Phase II efficacy and safety trial, significantly reducing the number of brain lesions in patients with relapsing-remitting multiple sclerosis (RRMS), ATL1103 drug designed to block GHR production which in a Phase II clinical trial, successfully reduced blood IGF-1 levels in patients with the growth disorder acromegaly, ATL1102 (inhaled) which is at the pre-clinical research stage as a potential treatment for asthma and ATL1101 a second-generation antisense drug at the pre-clinical stage being investigated as a potential treatment for cancer.

# CORTENDO

## **Cortendo Announces Plans to Conduct Registered Initial Public Offering of Its Common Shares**

July 20, 2015 – Göteborg, Sweden and Treviso, Pa., USA – Cortendo AB (publ) [ticker: CORT on NOTC-A] today announced that the Company plans to conduct a registered initial public offering of common shares in the United States.

This announcement is being made pursuant to and in accordance with Rule 135 under the Securities Act of 1933. As required by Rule 135, this press release does not constitute an offer to sell or the solicitation of an offer to buy securities, and shall not constitute an offer, solicitation or sale in any jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of that jurisdiction.

### **Contacts:**

#### **Cortendo AB:**

#### **Corporate and Media Relations**

Elixir Health Public Relations

Lindsay Rocco

+1 862-596-1304

[lrocco@elixirhealthpr.com](mailto:lrocco@elixirhealthpr.com)

#### **Investor Relations**

ICR Inc.

Stephanie Carrington

+1 646-277-1282

[Stephanie.Carrington@icrinc.com](mailto:Stephanie.Carrington@icrinc.com)

#### **Sweden**

Box 47

SE-433 21 Partille

Tel. / Fax. +46 (0) 31-263010

#### **USA**

900 Northbrook Drive

Suite 200

Treviso, PA 19053

Tel. +1 610-254-9200

Fax. +1 215-355-7389